

Marta Torrens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/585042/publications.pdf>

Version: 2024-02-01

95
papers

2,999
citations

186265

28
h-index

182427

51
g-index

99
all docs

99
docs citations

99
times ranked

3546
citing authors

#	ARTICLE	IF	CITATIONS
1	Opioid use and misuse in Europe: COVID-19 new challenges?. <i>European Neuropsychopharmacology</i> , 2022, 54, 67-69.	0.7	3
2	Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care. , 2022, 2, 100027.		2
3	Abuse Potential of Cathinones in Humans: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1004.	2.4	13
4	BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression. <i>Frontiers in Psychiatry</i> , 2022, 13, 836771.	2.6	2
5	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. <i>Biology</i> , 2022, 11, 645.	2.8	2
6	Lifetime Dual Disorder Screening and Treatment Retention: A Pilot Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3760.	2.4	1
7	Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 4038.	2.4	6
8	Clinical impact of COVID-19 on people with substance use disorders. <i>Journal of Public Health</i> , 2021, 43, 9-12.	1.8	16
9	Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans. <i>Pharmaceuticals</i> , 2021, 14, 100.	3.8	14
10	A Gender Perspective of Addictive Disorders. <i>Current Addiction Reports</i> , 2021, 8, 89-99.	3.4	44
11	Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4000.	4.1	19
12	A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure. <i>Biology</i> , 2021, 10, 788.	2.8	10
13	Sex-specific Associations of Alcohol Withdrawal in Patients Admitted for the Treatment of Alcohol Use Disorder. <i>Journal of Addiction Medicine</i> , 2021, 15, 68-73.	2.6	8
14	Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente. <i>Revista De Psicología De La Salud</i> , 2021, 33, 193.	0.5	5
15	Dual Disorders in the Consultation Liaison Addiction Service: Gender Perspective and Quality of Life. <i>Journal of Clinical Medicine</i> , 2021, 10, 5572.	2.4	4
16	Integration of harm reduction and treatment into care centres for substance use: The Barcelona model. <i>International Journal of Drug Policy</i> , 2020, 76, 102614.	3.3	6
17	Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. <i>BMC Infectious Diseases</i> , 2020, 20, 702.	2.9	9
18	Managing dual disorders: a statement by the Informal Scientific Network, <sc>UN</sc> Commission on Narcotic Drugs. <i>World Psychiatry</i> , 2020, 19, 396-397.	10.4	23

#	ARTICLE	IF	CITATIONS
19	Traumatic Events in Dual Disorders: Prevalence and Clinical Characteristics. <i>Journal of Clinical Medicine</i> , 2020, 9, 2553.	2.4	8
20	Alcohol Induced Depression: Clinical, Biological and Genetic Features. <i>Journal of Clinical Medicine</i> , 2020, 9, 2668.	2.4	9
21	The Tryptophan System in Cocaine-Induced Depression. <i>Journal of Clinical Medicine</i> , 2020, 9, 4103.	2.4	11
22	Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances. <i>Frontiers in Psychiatry</i> , 2020, 11, 612192.	2.6	9
23	Acute Effects of 2C-E in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 233.	3.5	11
24	MDMA interactions with pharmaceuticals and drugs of abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 357-369.	3.3	19
25	Oral Administration of Cannabis and Δ^9 -tetrahydrocannabinol (THC) Preparations: A Systematic Review. <i>Medicina (Lithuania)</i> , 2020, 56, 309.	2.0	38
26	Cannabis research: Risks of recreational use and potential medical applications. <i>European Neuropsychopharmacology</i> , 2020, 36, 167-168.	0.7	5
27	Effects of cannabis exposure in the prenatal and adolescent periods: Preclinical and clinical studies in both sexes. <i>Frontiers in Neuroendocrinology</i> , 2020, 57, 100841.	5.2	25
28	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	13.7	169
29	Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 131.	3.5	9
30	Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotonergic Effects, and Impact of <i>CYP2D6</i> Genetic Variation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 596-604.	4.7	17
31	Mephedrone and Alcohol Interactions in Humans. <i>Frontiers in Pharmacology</i> , 2019, 10, 1588.	3.5	21
32	Relationship between craving and impulsivity in patients with alcohol dependence with or without dual disorders in an outpatient treatment center: a descriptive study. <i>Actas Espanolas De Psiquiatria</i> , 2019, 47, 88-96.	0.1	4
33	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 1-10.	2.9	17
34	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 183-195.	3.3	15
35	The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis. <i>Addictive Behaviors</i> , 2018, 79, 52-60.	3.0	39
36	Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study. <i>Archives of Women's Mental Health</i> , 2018, 21, 259-269.	2.6	13

#	ARTICLE	IF	CITATIONS
37	Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 206.	3.5	38
38	Patología dual en Depresión: recomendaciones en el tratamiento. <i>Revista De Psicología De La Salud</i> , 2018, 30, 66.	0.5	29
39	Mephedrone Concentrations in Cases of Clinical Intoxication. <i>Current Pharmaceutical Design</i> , 2018, 23, 5511-5522.	1.9	66
40	Gender differences in lifetime psychiatric and substance use disorders among people who use substances in Barcelona, Spain. <i>Advances in Dual Diagnosis</i> , 2017, 10, 45-56.	0.5	5
41	An uncontrolled, feasibility study of a group intervention to reduce hepatitis C transmission risk behaviours and increase transmission knowledge among women who inject drugs. <i>Drugs: Education, Prevention and Policy</i> , 2017, 24, 179-188.	1.3	3
42	Dual Depression: A Sex Perspective. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, 180-186.	0.5	5
43	Population characteristics of methamphetamine shabu users. <i>European Psychiatry</i> , 2017, 41, S872-S872.	0.2	0
44	Text mining and expert curation to develop a database on psychiatric diseases and their genes. <i>Database: the Journal of Biological Databases and Curation</i> , 2017, 2017, .	3.0	11
45	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1987-1999.	1.8	96
46	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	3.3	54
47	The hidden web and the fentanyl problem: Detection of ocfentanyl as an adulterant in heroin. <i>International Journal of Drug Policy</i> , 2017, 40, 78-83.	3.3	64
48	Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity. <i>Frontiers in Psychiatry</i> , 2017, 7, 214.	2.6	25
49	A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (11-Imidazoline Receptor). <i>Frontiers in Psychiatry</i> , 2017, 8, 258.	2.6	6
50	Differences in the Rates of Drug Polyconsumption and Psychiatric Comorbidity among Patients with Cocaine Use Disorders According to the Mental Health Service. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 306-315.	1.7	11
51	Patología dual: una perspectiva europea. <i>Revista De Psicología De La Salud</i> , 2017, 29, 3.	0.5	22
52	Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 554-566.	1.4	29
53	Concurrent Use of Cannabis and Alcohol: Neuropsychiatric Effect Consequences. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 592-597.	1.4	6
54	Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders: a 36-month prospective pragmatic follow-up study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 1477.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study. <i>Psychiatry Research</i> , 2016, 243, 174-181.	3.3	44
56	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 313-331.	1.7	28
57	PCP analogues in samples of Barcelona from 2009 to 2015. <i>European Psychiatry</i> , 2016, 33, S117-S117.	0.2	1
58	Human Pharmacology of Mephedrone in Comparison with MDMA. <i>Neuropsychopharmacology</i> , 2016, 41, 2704-2713.	5.4	132
59	Can symptoms help in differential diagnosis between substance-induced vs independent psychosis in adults with a lifetime diagnosis of cocaine use disorder?. <i>Psychiatry Research</i> , 2016, 242, 94-100.	3.3	6
60	“Flakka”: an Emerging Trend Or a Mass Media Phenomenon? Presence of alpha-pvp in Samples Submitted To a Drug Checking Facility. <i>European Psychiatry</i> , 2016, 33, S442-S442.	0.2	2
61	Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center. <i>AIDS and Behavior</i> , 2016, 20, 1068-1075.	2.7	6
62	Factors associated with physical or sexual intimate partner violence perpetration by men attending substance misuse treatment in Catalunya: A mixed methods study. <i>Criminal Behaviour and Mental Health</i> , 2015, 25, 239-257.	0.8	26
63	Plasma Concentrations of BDNF and IGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity. <i>PLoS ONE</i> , 2015, 10, e0118610.	2.5	25
64	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	28
65	PsyGeNET: a knowledge platform on psychiatric disorders and their genes. <i>Bioinformatics</i> , 2015, 31, 3075-3077.	4.1	79
66	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart. <i>European Neuropsychopharmacology</i> , 2015, 25, 1637-1649.	0.7	24
67	Sex Differences in Psychiatric Comorbidity and Plasma Biomarkers for Cocaine Addiction in Abstinent Cocaine-Addicted Subjects in Outpatient Settings. <i>Frontiers in Psychiatry</i> , 2015, 6, 17.	2.6	31
68	Criteria and Concurrent Validity of Adult ADHD Section of the Psychiatry Research Interview for Substance and Mental Disorders. <i>Journal of Attention Disorders</i> , 2015, 19, 999-1006.	2.6	17
69	Quality of life in a community sample of young cocaine and/or heroin users: the role of mental disorders. <i>Quality of Life Research</i> , 2015, 24, 2129-2137.	3.1	17
70	Dual Diagnosis Screening Interview to Identify Psychiatric Comorbidity in Substance Users: Development and Validation of a Brief Instrument. <i>European Addiction Research</i> , 2014, 20, 41-48.	2.4	41
71	Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu010.	0.9	2
72	Temporal trends in the survival of drug and alcohol abusers according to the primary drug of admission to treatment in Spain. <i>Drug and Alcohol Dependence</i> , 2014, 136, 115-120.	3.2	5

#	ARTICLE	IF	CITATIONS
73	Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. <i>Journal of Psychiatric Research</i> , 2014, 51, 68-78.	3.1	88
74	Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. <i>Psychiatry Research</i> , 2014, 216, 398-403.	3.3	22
75	Role of <i>ALDH5A1</i> in methadone treatment. <i>Pharmacogenomics</i> , 2014, 15, 573-576.	1.3	0
76	ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. <i>European Neuropsychopharmacology</i> , 2014, 24, 420-424.	0.7	10
77	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2Åh apart. <i>Psychopharmacology</i> , 2013, 225, 883-893.	3.1	35
78	Methadone maintenance treatment in Spain: the success of a harm reduction approach. <i>Bulletin of the World Health Organization</i> , 2013, 91, 136-141.	3.3	44
79	Changes in CYP1A2 Activity in Humans after 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Administration Using Caffeine as a Probe Drug. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 605-613.	2.2	20
80	Exploring the relationship between intimate partner violence, childhood abuse and psychiatric disorders among female drug users in Barcelona. <i>Advances in Dual Diagnosis</i> , 2012, 5, 46-58.	0.5	12
81	Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT). <i>PLoS ONE</i> , 2012, 7, e47599.	2.5	48
82	Psychiatric Co-Morbidity and Substance Use Disorders: Treatment in Parallel Systems or in One Integrated System?. <i>Substance Use and Misuse</i> , 2012, 47, 1005-1014.	1.4	84
83	Risks factors for cocaine-induced psychotic disorder. <i>European Psychiatry</i> , 2011, 26, 96-96.	0.2	0
84	Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans. <i>Clinical Pharmacokinetics</i> , 2011, 50, 319-329.	3.5	27
85	Psychiatric comorbidity in illicit drug users: Substance-induced versus independent disorders. <i>Drug and Alcohol Dependence</i> , 2011, 113, 147-156.	3.2	127
86	Psychiatric, Behavioural and Social Risk Factors for HIV Infection Among Female Drug Users. <i>AIDS and Behavior</i> , 2011, 15, 1834-1843.	2.7	28
87	Accesibilidad a tratamiento en personas con problemas de Alcohol y otras Sustancias de abuso. <i>Revista De Psicología De La Salud</i> , 2011, 23, 343.	0.5	3
88	The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 523-529.	1.4	49
89	Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 954-962.	2.5	93
90	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 551-554.	1.9	42

#	ARTICLE	IF	CITATIONS
91	Efficacy of antidepressants in substance use disorders with and without comorbid depression. <i>Drug and Alcohol Dependence</i> , 2005, 78, 1-22.	3.2	226
92	Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. <i>Psychopharmacology</i> , 2004, 173, 364-375.	3.1	120
93	Diagnosing Comorbid Psychiatric Disorders in Substance Abusers: Validity of the Spanish Versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. <i>American Journal of Psychiatry</i> , 2004, 161, 1231-1237.	7.2	184
94	Methadone and quality of life. <i>Lancet</i> , The, 1999, 353, 1101.	13.7	54
95	Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. <i>Addiction</i> , 1992, 87, 55-62.	3.3	50